Sign inJoin waitlistJoin the waitlist

David Bajor

Clinical Assistant Professor of Medicine · Case Western Reserve University/University Hospitals Cleveland Medical Center

Credentials: · · · ·

History

Case Western Reserve University/University Hospitals Cleveland Medical Center
Present
Case Western Reserve University/University Hospitals Cleveland Medical Center
Present
Case Western Reserve University/University Hospitals Cleveland Medical Center
Present

Hematology and Medical Oncology
Hospital of the University of Pennsylvania
2010–2013
Hospital of the University of Pennsylvania
2007–2010
Case Western Reserve University School of Medicine
2003–2007
University Of Michigan
1998–2002

Research

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Journal of Clinical Oncology · 2007 · 443 citations
Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
New England Journal of Medicine · 2023 · 440 citations
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Cancer Immunology Research · 2015 · 385 citations

JS
Jennifer Selfridge
28 papers · 6 as a fellow
Amr Mohamed
24 papers · 19 as a fellow
Jeffrey Hardacre
19 papers
John Ammori
19 papers
Jordan Winter
19 papers
Lee Ocuin
18 papers
Amit Mahipal
15 papers
Jonathan Hue
12 papers · 12 as a resident
Luke Rothermel
11 papers · 1 as a fellow
Robert Vonderheide
11 papers
Joel Saltzman
10 papers
Sakti Chakrabarti
9 papers

Clinical trials

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
Principal investigator · Active not recruiting · Phase 1
Case Comprehensive Cancer Center
2022–2026
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
Principal investigator · Completed · Phase 1, Phase 2
David Bajor, MD
2018–2024
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Principal investigator · Completed · Phase 1, Phase 2
David Bajor, MD
2016–2023
Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
Principal investigator · Completed · Phase 2
Case Comprehensive Cancer Center
2013–2018